PL4177270T3 - Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 - Google Patents
Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47Info
- Publication number
- PL4177270T3 PL4177270T3 PL22199536.8T PL22199536T PL4177270T3 PL 4177270 T3 PL4177270 T3 PL 4177270T3 PL 22199536 T PL22199536 T PL 22199536T PL 4177270 T3 PL4177270 T3 PL 4177270T3
- Authority
- PL
- Poland
- Prior art keywords
- agent
- ovarian cancer
- cancer therapy
- based ovarian
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573835P | 2017-10-18 | 2017-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4177270T3 true PL4177270T3 (pl) | 2024-11-18 |
Family
ID=64267915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22199536.8T PL4177270T3 (pl) | 2017-10-18 | 2018-10-18 | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| PL18800381.8T PL3697817T3 (pl) | 2017-10-18 | 2018-10-18 | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18800381.8T PL3697817T3 (pl) | 2017-10-18 | 2018-10-18 | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11802153B2 (pl) |
| EP (2) | EP3697817B1 (pl) |
| JP (2) | JP7308191B2 (pl) |
| KR (1) | KR102776457B1 (pl) |
| CN (2) | CN111247172B (pl) |
| AU (1) | AU2018351006B2 (pl) |
| CA (1) | CA3078253A1 (pl) |
| ES (2) | ES2989007T3 (pl) |
| PL (2) | PL4177270T3 (pl) |
| PT (2) | PT4177270T (pl) |
| SI (2) | SI4177270T1 (pl) |
| WO (1) | WO2019079548A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3011097C (en) | 2016-01-11 | 2022-12-20 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| PL4177270T3 (pl) | 2017-10-18 | 2024-11-18 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| EP3752190B1 (en) | 2018-02-12 | 2022-07-06 | Forty Seven, Inc. | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies |
| EP3846855B1 (en) * | 2018-09-04 | 2024-12-04 | Pfizer Inc. | Cd47 blockade with parp inhibition for disease treatment |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| US20230081265A1 (en) * | 2020-04-06 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody formulation |
| EP4168449A1 (en) * | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
| CN117222413A (zh) * | 2021-02-10 | 2023-12-12 | 同润生物医药(上海)有限公司 | 治疗肿瘤的方法和组合 |
| WO2022218384A1 (zh) * | 2021-04-14 | 2022-10-20 | 中山康方生物医药有限公司 | 抗cd47的单克隆抗体及其用途 |
| EP4353265A4 (en) * | 2021-06-10 | 2024-10-02 | ONO Pharmaceutical Co., Ltd. | METHOD OF TREATING CANCER BY MEANS OF A COMBINATION OF A CD47 INHIBITOR, AN IMMUNE CHECKPOINT INHIBITOR AND STANDARD THERAPY |
| CN115245516A (zh) * | 2021-12-31 | 2022-10-28 | 郑州大学第一附属医院 | 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法 |
| WO2023172643A1 (en) * | 2022-03-08 | 2023-09-14 | Whitehead Institute For Biomedical Research | The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer |
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230391868A1 (en) * | 2022-06-02 | 2023-12-07 | The George Washington University | Compositions for and methods of treating cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| SI2477648T1 (sl) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| WO2011041453A1 (en) | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| SG10201401123VA (en) * | 2010-02-23 | 2014-08-28 | Genentech Inc | Anti-Angiogenesis Therapy For The Treatment Of Ovarian Cancer |
| AU2011252851B2 (en) | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| WO2012088309A1 (en) | 2010-12-21 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| MX2015007446A (es) | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| CN105189556A (zh) | 2013-03-15 | 2015-12-23 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| WO2014179132A1 (en) | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-cd47 agents to enhance immunization |
| US9945870B2 (en) | 2013-05-17 | 2018-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| EP3177640B1 (en) | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
| WO2016065329A1 (en) | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EP3247464B1 (en) | 2015-01-21 | 2019-09-18 | The Board of Trustees of the Leland Stanford Junior University | Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells |
| WO2016179399A1 (en) | 2015-05-06 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity cd47 analogs |
| US20180147257A1 (en) | 2015-05-22 | 2018-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| ES2894335T5 (es) | 2015-08-26 | 2024-06-27 | Univ Leland Stanford Junior | Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune |
| CN116425875A (zh) * | 2015-09-18 | 2023-07-14 | 安驰肿瘤公司 | 治疗性cd47抗体 |
| KR102988978B1 (ko) * | 2015-12-11 | 2026-07-10 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 |
| WO2017117196A1 (en) | 2015-12-28 | 2017-07-06 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer |
| CA3011097C (en) | 2016-01-11 | 2022-12-20 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| AU2017210224B2 (en) | 2016-01-21 | 2024-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
| KR20240016445A (ko) | 2016-04-15 | 2024-02-06 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 |
| EP3493845A4 (en) | 2016-08-03 | 2020-04-15 | The Board of Trustees of the Leland Stanford Junior University | INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY |
| WO2018031419A1 (en) | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
| EP3532497B1 (en) | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| EP4194470A1 (en) | 2017-10-18 | 2023-06-14 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| PL4177270T3 (pl) | 2017-10-18 | 2024-11-18 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| WO2019241403A1 (en) | 2018-06-13 | 2019-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis |
| US20220091104A1 (en) | 2018-09-28 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy |
| WO2020160285A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| WO2020163692A1 (en) | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
-
2018
- 2018-10-18 PL PL22199536.8T patent/PL4177270T3/pl unknown
- 2018-10-18 WO PCT/US2018/056441 patent/WO2019079548A1/en not_active Ceased
- 2018-10-18 ES ES22199536T patent/ES2989007T3/es active Active
- 2018-10-18 SI SI201831145T patent/SI4177270T1/sl unknown
- 2018-10-18 CN CN201880068424.8A patent/CN111247172B/zh active Active
- 2018-10-18 AU AU2018351006A patent/AU2018351006B2/en not_active Ceased
- 2018-10-18 SI SI201830808T patent/SI3697817T1/sl unknown
- 2018-10-18 PT PT221995368T patent/PT4177270T/pt unknown
- 2018-10-18 CA CA3078253A patent/CA3078253A1/en active Pending
- 2018-10-18 PL PL18800381.8T patent/PL3697817T3/pl unknown
- 2018-10-18 KR KR1020207014145A patent/KR102776457B1/ko active Active
- 2018-10-18 CN CN202311510416.3A patent/CN117771364A/zh active Pending
- 2018-10-18 EP EP18800381.8A patent/EP3697817B1/en active Active
- 2018-10-18 JP JP2020522016A patent/JP7308191B2/ja active Active
- 2018-10-18 ES ES18800381T patent/ES2932286T3/es active Active
- 2018-10-18 PT PT188003818T patent/PT3697817T/pt unknown
- 2018-10-18 EP EP22199536.8A patent/EP4177270B1/en active Active
- 2018-10-18 US US16/756,673 patent/US11802153B2/en active Active
-
2022
- 2022-11-22 JP JP2022186406A patent/JP2023018062A/ja active Pending
-
2023
- 2023-09-27 US US18/373,655 patent/US20240150461A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3078253A1 (en) | 2019-04-25 |
| ES2932286T3 (es) | 2023-01-17 |
| SI4177270T1 (sl) | 2024-10-30 |
| KR102776457B1 (ko) | 2025-03-06 |
| CN111247172A (zh) | 2020-06-05 |
| AU2018351006B2 (en) | 2024-08-29 |
| JP2021500349A (ja) | 2021-01-07 |
| EP4177270B1 (en) | 2024-07-31 |
| US20240150461A1 (en) | 2024-05-09 |
| PT4177270T (pt) | 2024-10-23 |
| AU2018351006A1 (en) | 2020-05-07 |
| EP4177270A1 (en) | 2023-05-10 |
| PL3697817T3 (pl) | 2023-01-23 |
| EP3697817B1 (en) | 2022-10-05 |
| US20200283520A1 (en) | 2020-09-10 |
| CN117771364A (zh) | 2024-03-29 |
| JP7308191B2 (ja) | 2023-07-13 |
| US11802153B2 (en) | 2023-10-31 |
| SI3697817T1 (sl) | 2023-01-31 |
| WO2019079548A1 (en) | 2019-04-25 |
| ES2989007T3 (es) | 2024-11-25 |
| EP3697817A1 (en) | 2020-08-26 |
| JP2023018062A (ja) | 2023-02-07 |
| KR20200068730A (ko) | 2020-06-15 |
| CN111247172B (zh) | 2023-11-14 |
| PT3697817T (pt) | 2023-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI4177270T1 (sl) | Terapija za raka jajčnikov na osnovi sredstva proti cd47 | |
| IL271946A (en) | Combination for cancer treatment | |
| GB201707153D0 (en) | Therapy | |
| SMT201800303T1 (it) | Trattamenti per il cancro | |
| PT3576740T (pt) | Tratamento de cancro | |
| GB201708663D0 (en) | Therapy | |
| GB201719646D0 (en) | Therapy | |
| IL268463A (en) | Cancer treatment | |
| DK3292140T3 (en) | Immunterapeutikum mod cancer | |
| GB201706451D0 (en) | Cancer treatment | |
| IL274626A (en) | Cancer treatment | |
| GB201519331D0 (en) | Treatment paradigm | |
| IL260814A (en) | Cancer treatment | |
| GB201707864D0 (en) | Platinum-reistant cancer treatment | |
| GB201519734D0 (en) | Cancer therapy | |
| GB201522433D0 (en) | Cancer treatment | |
| GB201704909D0 (en) | Cancer therapy | |
| GB201707500D0 (en) | New therapy | |
| GB201711855D0 (en) | Cancer therapy | |
| GB201706223D0 (en) | Combination therapy | |
| HK40037091A (en) | Gp96-based cancer therapy | |
| GB201711250D0 (en) | Cancer therapy | |
| GB201710198D0 (en) | Cancer therapy | |
| GB201706046D0 (en) | Cancer therapy | |
| HK40009559A (en) | Anti-cd47 combination therapy |